Petrelintide

DRUG7 trials

Sponsors

Zealand Pharma A/S, Zealand Pharma, Hoffmann-La Roche

Conditions

Impaired Hepatic FunctionObesityObesity & OverweightObesity or OverweightOverweightRenal ImpairmentType 2 DiabetesWeight management

Phase 1

Pharmacokinetics of Petrelintide Following Administration to Participants With Impaired Renal Function

CompletedNCT07076030

Zealand PharmaRenal Impairment

Start: 2025-04-15End: 2025-11-25Updated: 2026-01-28

Investigating the Pharmacokinetics of Petrelintide Using Different Drug Product Concentrations

CompletedNCT07338214

Zealand PharmaObesity & Overweight

Start: 2025-12-17End: 2026-03-31Updated: 2026-04-08

Pharmacokinetics of Petrelintide in Participants With Impaired Hepatic Function

RecruitingNCT07682818

Zealand PharmaImpaired Hepatic Function

Start: 2026-05-18End: 2027-04-12Target: 36Updated: 2026-07-06

Phase 2

Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities

CompletedNCT06662539

Zealand PharmaObesity

Start: 2024-12-09End: 2026-03-07Updated: 2026-03-23

A randomized, double-blind, Phase 2, dose-finding trial of once weekly petrelintide compared with placebo in participants with obesity or overweight with weight related comorbidities

Active, not recruitingCTIS2024-512549-18-00

Zealand Pharma A/SWeight management

Start: 2024-12-19Target: 220Updated: 2026-01-16

Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)

CompletedNCT06926842

Zealand PharmaObesity, Overweight, Type 2 Diabetes

Start: 2025-04-22End: 2026-08-13Updated: 2026-09-09

A Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Overweight

Not yet recruitingNCT07589686

Hoffmann-La RocheObesity or Overweight

Start: 2026-09-30End: 2028-01-31Target: 486Updated: 2026-09-09